Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
1.
Public Health ; 217: 190-195, 2023 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-36907028

RESUMO

OBJECTIVES: To analyze the rates of breast cancer survival among Black and White women according to age and stage at diagnosis. STUDY DESIGN: A retrospective cohort study. METHODS: The study examined women registered in the population-based cancer registry of Campinas in 2010-2014. The primary variable was the declared race (White or Black). Other races were excluded. Data were linked with the Mortality Information System, and missing information was accessed by active search. Overall survival (OS) was calculated by the Kaplan-Meier method, comparisons were done by chi-squared tests, and hazard ratios were examined by Cox regression. RESULTS: The total numbers of new cases of staged breast cancer among Black and White women were 218 and 1522 cases, respectively. The rates of stages III/IV were 35.5% among White women and 43.1% among Black women (P = 0.024). The frequencies among White and Black women under 40 years old were 8.0% and 12.4% (P = 0.031), 19.6% and 26.6% (P = 0.016) for ages of 40-49 years, and 23.8% and 17.4% (P = 0.037) for ages of 60-69 years, respectively. The mean OS was 7.5 years (7.0; 8.0) among Black women and 8.4 years (8.2; 8.5) among White women. The 5-year OS was 72.3% among Black women and 80.5% among White women (P = 0.001). Black women had an age-adjusted risk of death that was 1.7 times higher (1.33; 2.20). The risk was 6.4 times higher for diagnoses in stage 0 (1.65; 24.90) and 1.5 times for diagnoses in stage IV (1.04; 2.17). CONCLUSION: The 5-year OS for women with breast cancer was significantly lower among Black women than White women. Black women were more frequently diagnosed in stages III/IV, and their age-adjusted risk of death was 1.7 times higher. Differences in access to care may explain these differences.


Assuntos
População Negra , Neoplasias da Mama , Adulto , Idoso , Feminino , Humanos , Pessoa de Meia-Idade , Brasil/epidemiologia , Neoplasias da Mama/mortalidade , Estadiamento de Neoplasias , Estudos Retrospectivos , Taxa de Sobrevida , População Branca
2.
Minerva Stomatol ; 60(5): 271-8, 2011 May.
Artigo em Inglês | MEDLINE | ID: mdl-21597431

RESUMO

Osteochondroma (OC) is the most common benign tumor of long bones. However it is rarely found in the facial skeleton, being the coronoid process and mandibular condyle the most affected sites in this region. It basically consists in bone growth covered by cartilage. The etiology is still controversial: neoplastic, developmental, reparative and traumatic origins have been discussed in literature. The treatments of these lesions include total condylectomy or local resection of the lesion. This paper aims to report a case of a patient with history of trauma and possible fracture of the mandibular condyle in childhood, which in youth developed dentofacial deformity with severe facial asymmetry. The treatment consisted of resection of lesion both with maxillary and mandibular osteotomies associated with graft from the iliac crest bone. Actually, the patient is with a favorable aesthetic, without functional deficit and absence of lesion's recurrence.


Assuntos
Assimetria Facial/etiologia , Assimetria Facial/cirurgia , Neoplasias Mandibulares/complicações , Osteocondroma/complicações , Osteotomia de Le Fort , Feminino , Humanos , Índice de Gravidade de Doença , Adulto Jovem
3.
Cancer Chemother Pharmacol ; 48(4): 333-7, 2001 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-11710635

RESUMO

PURPOSE: The combination of bolus doxorubicin followed by a 3-h infusion of paclitaxel has high antitumor activity in patients with metastatic breast cancer, but is limited by unexpected cardiac toxicity. In contrast, the administration of the two drugs 16 h apart has similar antitumor activity but less cardiac toxicity. The purpose of this study was to compare the pharmacokinetics of these drugs when doxorubicin administration preceded paclitaxel by 30 min or by 24 h. PATIENTS AND METHODS: Women with locally advanced breast cancer were treated with doxorubicin (60 mg/m2 i.v. bolus) followed 24 h later by paclitaxel (200 mg/m2 i.v. over 3 h) for six cycles (four before and two after surgery). In one of the first two cycles doxorubicin preceded paclitaxel by 30 min instead of 24 h, with plasma sampling for pharmacokinetic analysis up to 48 h. Determination of drug levels in plasma was done by HPLC. RESULTS: A total of 28 patients were included. No clinical cardiac toxicity was observed but five patients discontinued doxorubicin-paclitaxel treatment after four cycles because of a decrease in LVEF of at least 15% from baseline or to less than 50%. While paclitaxel pharmacokinetics were not changed, there was a 30% and an 80% increase in the AUC0, 24h for doxorubicin and doxorubicinol, respectively, when the drugs were administered 30 min instead of 24 h apart. Even when paclitaxel was given 24 h after doxorubicin, there was a rebound 240% increase in the plasma concentration of doxorubicinol. CONCLUSIONS: Paclitaxel interferes with the pharmacokinetics of doxorubicin leading to higher systemic exposure to both doxorubicin and doxorubicinol, which is more evident when the plasma concentration of the anthracyclines is higher. This interference may explain the higher incidence of cardiac toxicity observed when the two drugs are administered within a short interval.


Assuntos
Antineoplásicos Fitogênicos/administração & dosagem , Antineoplásicos Fitogênicos/farmacocinética , Antineoplásicos/efeitos adversos , Antineoplásicos/farmacocinética , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/farmacocinética , Neoplasias da Mama/tratamento farmacológico , Doxorrubicina/efeitos adversos , Doxorrubicina/farmacocinética , Paclitaxel/administração & dosagem , Paclitaxel/farmacocinética , Adulto , Antineoplásicos/administração & dosagem , Antineoplásicos Fitogênicos/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Área Sob a Curva , Doxorrubicina/administração & dosagem , Esquema de Medicação , Interações Medicamentosas , Feminino , Coração/efeitos dos fármacos , Humanos , Infusões Intravenosas , Injeções Intravenosas , Pessoa de Meia-Idade , Paclitaxel/efeitos adversos , Volume Sistólico
4.
Nurs Health Care Perspect ; 22(1): 20-5, 2001.
Artigo em Inglês | MEDLINE | ID: mdl-11221176

RESUMO

This article describes the process of curriculum change in a baccalaureate nursing program and the design of a competency-oriented learning system in primary health care, community-focused nursing education.


Assuntos
Enfermagem em Saúde Comunitária/educação , Educação Baseada em Competências/organização & administração , Bacharelado em Enfermagem/organização & administração , Pesquisa em Avaliação de Enfermagem/métodos , Atenção Primária à Saúde , Currículo , Humanos
5.
Nurs Clin North Am ; 35(1): 267-78, 2000 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-10673580

RESUMO

Sjögren's syndrome is an autoimmune disorder characterized by lymphocytic infiltration of salivary and lacrimal glands. The systemic production of autoantibodies leads to dry eyes, dry mouth, and other symptoms related to decreased salivary and lacrimal gland function in patients with Sjögren's syndrome. This article discusses origins, epidemiology, contributing factors, symptoms, assessment, diagnostic studies, management, expected outcomes, and research concerning Sjögren's syndrome.


Assuntos
Antirreumáticos/uso terapêutico , Hidroxicloroquina/uso terapêutico , Enfermagem Prática , Síndrome de Sjogren , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Prevalência , Síndrome de Sjogren/diagnóstico , Síndrome de Sjogren/tratamento farmacológico , Síndrome de Sjogren/enfermagem , Síndrome de Sjogren/fisiopatologia
6.
J Am Acad Nurse Pract ; 9(3): 143-7, quiz 148-9, 1997 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-9287655

RESUMO

The primary prevention of lung cancer is to avoid and decrease the use of tobacco. Further research could include studying the effects of culture, ethnicity, and geographic location on smoking. Education needs to start early in the educational systems. At present there are programs for primary grades on drug and alcohol abuse and how to say "no." Education also needs to include the family when the parents are smokers, as their children are exposed to second-hand smoke and are led by example. Certain religious groups believe it is their duty to keep healthy and, therefore, do not smoke. These groups may be able to provide some answers as to how to prevent people from smoking. Prevention--it is our real hope.


Assuntos
Neoplasias Pulmonares/terapia , Idoso , Terapia Combinada , Diagnóstico por Imagem , Feminino , Humanos , Neoplasias Pulmonares/diagnóstico , Neoplasias Pulmonares/epidemiologia , Masculino , Pessoa de Meia-Idade , Fumar/epidemiologia , Estados Unidos/epidemiologia
7.
Arq Neuropsiquiatr ; 46(2): 198-200, 1988 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-3202719

RESUMO

The Holmes-Adie syndrome consists of pupillotonia, arreflexia and autonomic dysfunction. Some explanations for these different symptoms have been attempted, centred upon neuropathological and electrophysiological findings. A hypothetical immunemediated mechanism, as in the Guillain Barré syndrome, is presented in this paper for explaining the three chief symptoms of the syndrome.


Assuntos
Síndrome de Adie/imunologia , Humanos
8.
Arq. neuropsiquiatr ; 46(2): 198-200, jun. 1988.
Artigo em Inglês | LILACS | ID: lil-57200

RESUMO

A síndrome de Holmes-Adie consiste de pupila tônica, arreflexia patelar e disfunçäo autômica. As explicaçöes desses diferentes síntomas têm-se baseado em achados neuropatológicos e eletrofisiológicos. Neste trabalho apresenta-se uma hipótese imunológica para a fisiopatogenia da síndrome, de modo semelhante à da síndrome de Guillain-Barré


Assuntos
Humanos , Síndrome de Adie/imunologia
12.
Transfusion ; 20(4): 440-2, 1980.
Artigo em Inglês | MEDLINE | ID: mdl-7404642

RESUMO

A sixth example of a potent autoanti-M is described in a nongravida, nontransfused Caucasian woman. The anti-M was still present after a period of 12 months without any apparent cause.


Assuntos
Autoanticorpos , Sistema do Grupo Sanguíneo MNSs , Absorção , Temperatura Baixa , Feminino , Humanos , Sistema do Grupo Sanguíneo I , Imunoglobulina M , Mercaptoetanol/farmacologia , Pessoa de Meia-Idade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...